Greenwich LifeSciences (GLSI) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q32 Bio (QTTB) has outperformed Greenwich LifeSciences (GLSI) over the past year, gaining 170.6% versus a gain of 32.3%. Over five years, GLSI leads with a -60.1% price change compared with -92.8% for QTTB. Q32 Bio is the larger company by market cap ($240.8 million vs $222.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | QTTB |
|---|---|---|
| Share price | $15.14 | $8.09 |
| Market cap | $222.23M | $240.83M |
| 1-day change | -1.62% | +1.25% |
| YTD return | -27.94% | +143.67% |
| 1-year return | +32.28% | +170.57% |
| 5-year return | -60.12% | -92.75% |
| P/E ratio (TTM) | — | 2.57 |
| EPS (TTM) | $-1.53 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $23.57 |
| 52-week low | $7.78 | $1.91 |
| Distance from 52-week high | -55.60% | -65.68% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +276.49% | +389.49% |
| Average volume | 138.91K | 1.38M |
| Shares outstanding | 14.68M | 29.77M |
| Employees | — | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed GLSI by 138.3 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
GLSI vs QTTB FAQ
Which is bigger, Greenwich LifeSciences or Q32 Bio?
Q32 Bio (QTTB) is larger, with a market capitalization of $240.83M compared with $222.23M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or QTTB?
QTTB returned +170.57% over the past 12 months, compared with +32.28% for GLSI (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Q32 Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.